If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful, it could lead to a pipeline of pro-drug chemotherapies with limited toxicity, say the drug's developers.
List view / Grid view
Filter the results
A study has shown that the use of oral contraceptives gave women a much lower risk of developing both ovarian and endometrial cancer.
The European Commission (EC) has approved Zejula, the first PARP-inhibitor monotherapy approved in the EU for patients with advanced ovarian cancer, regardless of their biomarker status.
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
The EMA has recommended granting marketing authorisation to two medicines and extending the indications for three more following its latest meeting.
The developers of Zejula (niraparib) have announced the FDA will assess the sNDA application under the Real-Time Oncology Review (RTOR) pilot programme.
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
NICE has recommended olaparib tablets (Lynparza, AstraZeneca) for adults with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer with a BRCA1 or BRCA2 mutation.
The UK NICE has extended its approval for olaparib, updating its formulation from eight capsules twice a day to two tablets twice daily.
BRCA-mutated advanced ovarian cancer treatment has been approved by the European Commission.
INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer...
Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors...